Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057889 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00057889: Completed Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00057889 is a Phase 2 study that has completed, run by National Institutes of Health Clinical Center (CC). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057889, a Phase 2 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have metastatic renal cell cancer (kidney cancer) that is refractory to treatment with interleukin-2 or unable to be treated with interleukin-2.
Interventions
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-02 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00057889 record still lists
NCT00057889 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ipilimumab is the first listed.
NCT00057889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057889 about?
NCT00057889 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have metastatic renal cell cancer (kidney...
What is the current status of trial NCT00057889?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-02. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00057889?
The interventions under investigation include: ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00057889?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia